Clinical Trial Update: ACAM 3000 MVA at Harvard Medical School [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial of the ACAM 3000 MVA smallpox vaccine sponsored by NIAID was conducted at Harvard Medical School, with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• ACAM 3000 MVA (Modified Vaccinia Ankara-based smallpox vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Smallpox | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2009-07-08